DDInter704 DDInter782
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting . Fosnetupitant is the pro-drug form of netupitant [FDA label]. Generally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality and 70% to 80% of these patients undergoing chemotherapy treatment may experience nausea and vomiting as major side effects. Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies .
Everolimus {u} (Compound) resembles {v} (Compound) Pimecrolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Everolimus {u} (Compound) treats {v} (Disease) kidney cancer
Everolimus {u} (Compound) binds {v} (Gene) FKBP1A
Everolimus {u} (Compound) upregulates {v} (Gene) USP20
Everolimus {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2D6 Inhibitors
Everolimus {u} (Compound) downregulates {v} (Gene) ATF1
Everolimus {u} (Compound) causes {v} (Side Effect) Pericardial effusion
Everolimus (Compound) resembles Pimecrolimus (Compound)
Everolimus (Compound) resembles Temsirolimus (Compound)
Everolimus (Compound) treats kidney cancer (Disease)
Everolimus (Compound) binds FKBP1A (Gene)
Everolimus (Compound) upregulates USP20 (Gene)
Everolimus (Compound) is included by Cytochrome P450 2D6 Inhibitors (Pharmacologic Class)
Everolimus (Compound) downregulates ATF1 (Gene)
Everolimus (Compound) causes Pericardial effusion (Side Effect)